Immune Cell Engineering Market Report: Market Size & Forecast 2026

Immune cell engineering involves modifying a patient's or donor's immune cells, most notably T lymphocytes and NK cells, to enhance their ability to recognize and destroy diseased cells. CAR-T cell therapy, which reprograms T cells to target cancer-specific antigens, remains the most commercially established platform, with approved products now marketed in major healthcare markets worldwide. The sector also encompasses manufacturing technologies, cell processing equipment, cryopreservation systems, and genomic editing tools such as CRISPR, which together constitute the cell therapy technologies market valued at approximately $4.7 billion globally in 2025.

• •The global cell therapy technologies market is valued at roughly $4.7 billion in 2025 and forecast to reach $7.91 billion by 2030 at a 12.4% CAGR.
• •The broader T-cell therapy market is estimated at $10.3 billion in 2025, with projections extending toward $196 billion by 2035.
• •Key engineered cell types include CAR-T, TCR-T, and NK cell therapies, alongside emerging allogeneic (off-the-shelf) product candidates.

The increasing global burden of cancer, particularly hematologic malignancies and solid tumors, has created sustained demand for innovative immunotherapy solutions. Breakthroughs in gene-editing technologies, viral and non-viral vector systems, and automated cell manufacturing have accelerated the translation of laboratory discoveries into clinically approved products. Regulatory agencies have established clearer pathways for cell and gene therapy approvals, shortening time-to-market and encouraging pharmaceutical investment in the space.

• •Rising cancer incidence and limited efficacy of conventional treatments are driving clinical adoption of engineered cell therapies.
• •Advances in CRISPR, lentiviral and retroviral transduction, and closed-system manufacturing are improving scalability and cost-efficiency.
• •Stringent yet increasingly mature regulatory frameworks, including accelerated approval mechanisms, are enabling faster market entry for novel cell therapy products.

The market is segmented by therapy type, autologous (patient-specific), allogeneic (donor-derived), and neo-antigen targeted approaches, and by therapeutic area, with oncology representing the dominant application. Approved CAR-T products targeting hematologic cancers such as lymphoma, leukemia, and multiple myeloma have driven the largest share of commercial revenue, while pipeline programs increasingly target solid tumors. North America leads globally due to strong biopharmaceutical infrastructure, favorable regulatory conditions, and high healthcare spending, while Europe and the Asia-Pacific region are expanding rapidly.

• •Oncology accounts for the dominant share of the market, with hematologic malignancies leading and solid tumor indications gaining clinical momentum.
• •North America holds the largest regional share, with Europe and Asia-Pacific emerging as high-growth markets driven by increasing clinical trial activity and regulatory approvals.
• •Autologous therapies dominate current commercial availability, while allogeneic and universal donor platforms represent the fastest-growing pipeline segment.

What are the recent trends and outlook?

The sector is moving toward next-generation cell therapies with enhanced safety profiles, including armored CAR-T constructs, dual-targeting mechanisms, and off-the-shelf allogeneic platforms designed to lower costs and improve accessibility. Integration of artificial intelligence and machine learning in target discovery, biomarker identification, and manufacturing optimization is expected to further accelerate product development timelines. Continued clinical successes in new indications, including autoimmune diseases, solid tumors, and degenerative conditions, will broaden the addressable market substantially over the coming decade.

• •Allogeneic (off-the-shelf) cell therapies and gene-edited universal donor cells are emerging as key cost-reduction and scalability strategies.
• •Combination therapies pairing engineered immune cells with checkpoint inhibitors, targeted agents, and radiation are under active clinical investigation.
• •Expansion into non-oncology indications, including autoimmune diseases, inflammatory conditions, and regenerative medicine, represents a significant long-term growth avenue.